secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hemab Therapeutics Holdings, Inc. (COAG)
CIK:        0002114044
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-203988
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M
---------------------------------------------------------------------------

- IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.
- Gross proceeds of $346.7 million before underwriting discounts and estimated offering expenses.
- Common stock begins trading on Nasdaq Global Select Market under ticker 'COAG'.
- Restated certificate increases authorized common shares to 400M, establishes classified board with staggered three-year terms.
- Stockholder written consent and special meeting rights eliminated; exclusive forum provisions adopted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/d149100d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-203988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer